Palonosetron effectively prevents and manages delayed chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphoma (NHL), according to a study published in Supportive Care in Cancer.

This study enrolled 40 chemotherapy naïve patients diagnosed with NHL. All patients received cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) as first-line therapy, and received intravenous (IV) palonosetron 0.75 mg over 30 minutes prior to CHOP on day 1 of cycles 1 and 2. 

Patients were assessed for nausea and vomiting through days 1 to 5 after the start of chemotherapy, and were stratified into acute (0-24 hours), delayed (24-120 hours), and overall (0-120 hours) phases of day 1 from both CHOP cycles. Patients self-reported any relevant palonosetron efficacy information.

Those in the acute, delayed, and overall phases after the first cycle demonstrated complete response (CR) rates of 92.5%, 85%, and 85%, respectively, and complete control (CC) rates of 82.5%, 70%, and 62.5%, respectively.

Patients in the acute, delayed, and overall phases after the second cycle demonstrated complete response (CR) rates of 95.0%, 95.0%, and 92.5%, respectively, and complete control (CC) rates of 85.0%, 85.0%, and 80.0%, respectively.

Overall, more than 85% of patients in both cycles achieved CR. CR in the delayed phase increased from 85% in cycle 1 to 95% in cycle 2. CC in the delayed phase increased from 70% from cycle 1 to 85% in cycle 2.

The authors of the study conclude that “palonosetron should be considered effective to prevent CINV in NHL patients treated with the CHOP regimen.”

Reference

1. Saito B, Nakashima H, Abe M, et al. Efficacy of palonosetron to prevent delayed nausea and vomiting in non-Hodgkin’s lymphoma patients undergoing repeated cycles of the CHOP regimen [published online August 2, 2017]. Support Care Cancer. doi: 10.1007/s00520-017-3845-y